Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Female condom approved

This article was originally published in The Gray Sheet

Executive Summary

The Female Health Company is building manufacturing capacity for its second generation FC2 female condom after receiving PMA approval March 11. The device is cleared to prevent pregnancy, HIV/AIDS and other sexually transmitted infections, and is expected to cost up to 30% less than the firm's original FC female condom. The company hopes that the lower price will boost sales to HIV prevention programs in the U.S. and globally. While the device is currently available overseas and FHC has the capacity to make 30 million units annually, it is aiming to boost production to 75-80 million units a year, the company states. FC2 approval was recommended by FDA's Obstetrics and Gynecology Devices Panel Dec. 11 (1"The Gray Sheet" Dec. 15, 2008, p. 14)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel